Abstract
Aim: Measures of atherogenic cholesterol, both with and without concomitant use of lipid-lowering medications (LLMs), are reported up to 52 weeks of sebelipase alfa (SA) treatment in children and adults with lysosomal acid lipase deficiency (LAL-D) participating in the phase 3 ARISE study (NCT01757184).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
